EGFR and neoplasm: All had biopsy-proven adenocarcinoma, 18 (94.6%) had tumours harbouring an EGFR mutation (exon 19 deletion, n = 6; exon 21 L858R, n = 10; exon 20 S768I, n = 1; exon 18 G719X, n = 1) and 1 (5.3%) harbouring an ELM4-ALK fusion.